TW202115090A - 巨環激酶抑制劑之多晶型 - Google Patents

巨環激酶抑制劑之多晶型 Download PDF

Info

Publication number
TW202115090A
TW202115090A TW109120778A TW109120778A TW202115090A TW 202115090 A TW202115090 A TW 202115090A TW 109120778 A TW109120778 A TW 109120778A TW 109120778 A TW109120778 A TW 109120778A TW 202115090 A TW202115090 A TW 202115090A
Authority
TW
Taiwan
Prior art keywords
cancer
ret
polymorphic form
crystalline
powder
Prior art date
Application number
TW109120778A
Other languages
English (en)
Chinese (zh)
Inventor
維 鄧
埃文 W 羅杰斯
躍列 盧
張晗
靖 劉
Original Assignee
美商特普醫葯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商特普醫葯公司 filed Critical 美商特普醫葯公司
Publication of TW202115090A publication Critical patent/TW202115090A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW109120778A 2019-06-19 2020-06-19 巨環激酶抑制劑之多晶型 TW202115090A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US62/863,493 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US62/959,940 2020-01-11
US202063036102P 2020-06-08 2020-06-08
US63/036,102 2020-06-08

Publications (1)

Publication Number Publication Date
TW202115090A true TW202115090A (zh) 2021-04-16

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109120778A TW202115090A (zh) 2019-06-19 2020-06-19 巨環激酶抑制劑之多晶型

Country Status (15)

Country Link
US (1) US20220411439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986413A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022537385A (cg-RX-API-DMAC7.html)
KR (1) KR20220046549A (cg-RX-API-DMAC7.html)
CN (1) CN114025765A (cg-RX-API-DMAC7.html)
AU (1) AU2020294627A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025786A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143043A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000405A2 (cg-RX-API-DMAC7.html)
IL (1) IL288982A (cg-RX-API-DMAC7.html)
MX (1) MX2021015756A (cg-RX-API-DMAC7.html)
PE (1) PE20220135A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553174A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115090A (cg-RX-API-DMAC7.html)
WO (1) WO2020257169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (ru) * 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CA3069554A1 (en) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
RS63787B1 (sr) * 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti

Also Published As

Publication number Publication date
PH12021553174A1 (en) 2022-08-01
WO2020257169A1 (en) 2020-12-24
MX2021015756A (es) 2022-01-27
AU2020294627A1 (en) 2022-02-17
IL288982A (en) 2022-02-01
PE20220135A1 (es) 2022-01-27
JP2022537385A (ja) 2022-08-25
BR112021025786A2 (pt) 2022-02-01
KR20220046549A (ko) 2022-04-14
CA3143043A1 (en) 2020-12-24
EP3986413A4 (en) 2023-06-14
CN114025765A (zh) 2022-02-08
CO2022000405A2 (es) 2022-04-29
US20220411439A1 (en) 2022-12-29
EP3986413A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
JP7212713B2 (ja) ジアリール大環状多形
CN111511746B (zh) 用于治疗疾病的巨环化合物
US7173029B2 (en) Fused heteroaryl derivatives
US20220017520A1 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
CN1608062A (zh) E-2-甲氧基-n-(3-{4-[3-甲基-4-(6-甲基-吡啶-3-基氧基) -苯氨基]-喹唑啉-6基}-烯丙基)-乙酰胺的盐,其制备和抗癌用途
JP2019518776A (ja) Egfr阻害剤としてのアニリンピリミジン化合物の結晶
IL293458A (en) Macro rings for use in the treatment of the disease
CN115160309B (zh) Krasg12c突变蛋白杂环类抑制剂的制备及其应用
US20220411439A1 (en) Polymorphs of a macrocyclic kinase inhibitor
CN118652239A (zh) 一类egfr别构抑制剂的合成及其用途
JP2006512355A (ja) E−2−メトキシ−n−(3−{4−[3−メチル−4−(6−メチルピリジン−3−イルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アリル)−アセトアミドの複合体、それらの製造方法および使用
WO2022121967A1 (zh) Egfr酪氨酸激酶抑制剂及其用途
HK40059224A (en) Diaryl macrocycle polymorph and method for preparing the same
HK40059224B (en) Diaryl macrocycle polymorph and method for preparing the same
HK1254492B (en) Diaryl macrocycle polymorph
HK1071743A (en) Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer